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ABSTRACT 
B-Chronic Lymphocytic Leukemia (B-CLL) usually follows an adverse, relentless clinical course by slowly developing 
drug resistance to fludarabine and other chemotherapeutic agents, as well as by acquiring new different genetic 
abnormalities. As B-CLL cells spontaneously produce high amounts of Reactive Oxygen Species (ROS) having an 
altered redox state in relation to that of normal B lymphocytes, we decided to probe different metal Zinc nanoparticles 
(ZnNPs) and quantify the levels of Singlet Oxigen (SO) to see if variations of its intracellular concentrations could 
execute and accelerate deadly programs in leukemic cells rather than in normal B lymphocytes, when applied with 
Photodynamic Therapy (PDT). In this way, we developed and tested a variety of metal ZnNPs of which one made of 
0.5% Manganese Doped Zinc Oxide (ZnO:Mn) was finally selected for further testing as it had the best fludarabine 
resistant B-CLL cells in vitro killing activity, specially when combined with PDT. An interesting and rapidly dying 
process of B-CLL cells, known as autophagy, was always seen under Transmission Electronic Microscopy (TEM) when 
incubated with these 0.5% Mn doped ZnO NPs. This phenomenon correlated well with those intracellular increases of 
SO when PDT was administered, and measured by a novel method first described by us. As this therapy seems to be very 
specific to fludarabine resistant B-CLL cells, producing almost no damage to normal lymphocytes, it could surely 
contribute in the near future as a new innovative targeted strategy to be delivered in the clinical setting for the definitive 
benefit of these bad prognostic patients. 
 
INTRODUCTION 
B-CLL and other chronic indolent hematologic 
malignancies like B lymphomas, are diseases which 
usually originate from hematopoietic B cells with 
abnormal alterations in the processes of development, 
maturation and/or apoptosis. They usually manifest as 
progressive accumulations of morphologically mature B 
lymphocytes although immunologically dysfunctional1. 
B-CLL is the most common adult leukemia in the western 
world and currently it has no available curative strategy2. 
Chemotherapy is still a valid alternative for its temporary 
improvement or just for tumor mass reduction, but not for 
a definitive healing treatment modality3. Gompertz´s , as 
well as Goldie & Coldman and Skipper concepts, have 
resulted in an enormous contribution to plan the 
administration of various antineoplastic drugs4,5. We have 
learned from them, about the importance of associating 
different drugs to avoid drug resistance. But this 
treatment approach usually leads to many complications 
and severe adverse effects for the patients6,7. New drugs, 
monoclonal antibodies as well as many other biologics 
have shown real improvements as anti-neoplastic 
therapies8,9, but in general, the side effects are still also 
frequent and the development of resistance or relapse are 
usually inevitable in this type of diseases10-12. The gold 
standard of any oncologyc drug should be to submit the 
malignant cells to an apoptotic or cytotoxic program, 
without involving healthy ones, thereby minimizing 
adverse effects and maximizing the expected results, 
specially in those situations in which drug resistance has 
developed13-15 . Therefore, it is essential to think of new 
therapeutic modalities in order to increase the needed 
pharmacolocical effects, providing greater biological 
activity and much more specificity for diseases like B- 
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CLL.  Nanotechnology, the science that studies, develops 
and employs nanometer-scale complex systems, has 
claimed to be the key to improve treatment outcomes in 
oncology16-18. Then, NPs, objects of a size of tens to  
hundreds of nanometers, constructed with different 
materials such as natural or synthetic polymers or even 
metals, could be custom designed almost for every 
disease including B-CLL and other lymphomas19-21.  
These elements when made of ZnO are plausible to be 
coated and modified by other elements and generate 
apoptotic and/or cytotoxic changes in malignant cells 
especially in the shape of autophagy. This specialized 
way of tumor cell death seems to be the specific result of 
metal NPs action and could be an interesting and 
innovative mechanism to be full discovered and achieved 
in cancer treatment22-24. ZnO NPs doped with metals such 
as Mn may have their optical and electronic properties 
modified as Mn is known to increase these NP´s surface 
defects, thus generating photo-oxidation reactions that 
could be enhanced by PDT25-27. These NPs, if excited by 
the correct light emission may generate ROS specially 
SO that could lead to an induced apoptotic process or 
some other kind of death pathway like autophagy in B-
CLL cells, including those with resistant phenotypes to 
conventional therapies2,3. This strategy could be a very 
specific one, considering that the level of oxidative stress 
found in leukemic cells is supposed to be a lot much 
higher than that of normal B lymphocytes28,29. Based on a 
growing body of evidence, ROS production is proposed 
as a key cytotoxic mechanism mediated by ZnO NPs 
leading to cell death30,31. Photo-activation of these ZnO 
NPs is predicted to induce greater levels of ROS 
including intracellular SO release which, if effectively 
targeted to cancer cells, could produce their selective 
final destruction26,27. Measurement of SO in biological 
environments is a major task specially when intracellular 
values, without interferences from the external medium, 
are required. Near-infrared (NIR) luminescence at 1270 
nm in cell environments is confounded by the strongly 
reduced SO lifetime and probably had never been 
achieved until a research group developed a NIR-
sensitive photomultiplier tube probe that allowed to 
clearly identify and measure a true intracellular 
component of SO signal32,33.  All these few described 
methods are expensive and required of a complex 
technology to be performed. PDT is a clinically tested 
promising technique to treat cancer. PDT uses light to 
activate light-sensitive drugs (photosensitizers) to 
produce short lived cytotoxic species such as SO to 
destroy malignant cells34,35 and could be associated 
therapeutically with NPs17,18 for this pourpose.  In this 
way, it was thought that NPs made of ZnO in 
 
 
Fig 1. Effect of three different doses of each of the 8 NPs 
tested on the viability of B-CLL cells at 48 hs. of 
incubation after PDT. 0.2 mg/ml produced the most 
intense killing activity. Increasing this dose up to 0.3 
mg/ml did not produce further significant increase in cell 
mortality as seen with 0,2 mg/ml. 
Fig 2. Cytotoxicity levels of B-CLL cells (L) from 5 patients 
and Normal B Lymphocytes (H) from 5 healthy donors for 
each NP at 24  and 48 h with and without laser irradiation. 
Clearly the most intense mortality is observe in B-CLL cells 
exposed to NPs2 at 48 hs and laser irradiated. 
 
 
Fig 3. TEM images in which formation of double 
membrane bound organelles in  B CLL cells is observed 
when treated with 0.5% Manganese doped  ZnO NPs and 
PDT. These organelles are autophagosomes and the cell 
dying process undoubtly is Autophagy.  
 
Fig 4. B-CLL cells incubated during two hours with SOSG 
and observed under fluorescent microscopy   
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combination with PDT, could be used to  promote 
cytotoxic specific effects on B-CLL cells but specially on 
those resistant to conventional therapies.  
 
MATERIALS AND METHODS 
Procurement and Manipulation of Cells: B-CLL cells  
from 5 patients (L), with un-mutated Ig VH, known to be 
clinical resistant to fludarabine7,14, as well as normal B  
lymphocytes from 5 healthy subjects (H), were obtained 
after informed consent. Both types of cells (L and H) 
were isolated from blood samples by density gradient 
centrifugation, using a Ficoll-Hypaque separation 
technique followed by a highly specific purifying method 
using a B Cell Isolation Kit developed for the fast and 
efficient separation of untouched B cells from human 
PBMCs by negative selection. This is an indirect 
magnetic labeling system. Non-B cells, for example, T 
cells, NK cells, dendritic cells, monocytes, granulocytes, 
and erythroid cells, are indirectly magnetically labeled by 
using a cocktail of biotin- conjugated antibodies against 
CD2, CD14, CD16, CD36, CD43, CD235a (Glycophorin 
A), and Anti-Biotin Micro-Beads. Isolation of highly pure 
B cells is achieved by depletion of magnetically labeled 
cells using MACS® columns (Miltenyi Biotec GmbH) 
[36][37][38]. Cells were then incubated at a concentration 
of 2x106 cells/ml in RPMI 1640 medium with 10% Fetal 
Bovine Serum (FBS) (Invitrogen) at 5% CO2 and 37°C 
overnight, before NPs testing was started. The next 
morning, 2x106 cells/ml of medium were harvested to 
determine basal apoptosis and/or viability. Cells not 
exposed to NPs served as controls in every experiment. 
After this testing cells were incubated with NPs at 
  
Fig 5. (a) Quantitative comparison of the intracellular SO 
generation after PDT by a fluorescent probe SOSG 
between normal lymphocytes and  B-CLL cells from 5 
healthy donors and 5 CLL patients treated with 0.5% Mn 
doped ZnO NPs. 
Fig 6(a). Quantitative comparison of the intracellular SO 
generated after PDT by fluorometry quantitative analysis 
of photooxidation reactions using DPBF as quencher 
between normal lymphocytes and B-CLL cells 
penetrated by Mn 0.5% doped ZnO.   
 
 
 Fig 5. (b) Singlet oxygen Sensor Green (SOSG) Quantum 
Yield (QY) of  Mn 0.5% doped ZnO NPs inside Normal 
Lymphocytes and B-CLL cells 
Fig 6. (b) Singlet oxygen (SO) Quantum Yield (QY) 
generated in Normal Lymphocytes and B-CLL cells 
penetrated by Mn 0.5% doped ZnO after PDT. 
 
 
Fig 7.  Apoptosis levels for Irradiated and Non-Irradiated 
B-CLL Cells and Normal B Lymphocytes Cultured with 
0.5% Mn doped ZnO NPs (NPs #2) at 24 hs detected by 
flow cytometric analysis (annexin V/PI double staining) 
 
Fig 8. Comparison of the mean IC50 of 0.5% Mn doped 
ZnO NPs on B-CLL cells (n = 5) and normal  B 
lymphocytes (n = 5). 
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different concentrations and times for all the penetration 
and mortality/viability experiments. Viability as well as 
degree of mortality/apoptosis of both cells, malignant and 
normal, were measured by the use of vital dyes staining 
techniques and fluorescence microscopy observation, 
MTT (4,5dimethylthiazol-2-5diphenyltetrazolium) probes 
and flow cytometry, as will be explained with more 
details later on. 
Synthesis of NPs: Eight different types of  Zinc (Zn) NPs 
were synthesized by different methods as described here: 
NP1 Zinc Oxide (ZnO), NP2 ZnO:Mn 0.5%, NP3 
ZnO:Mn 1.0%, NP4 ZnO:Mn 1.5%, NP5 ZnO:Mn 2.0%, 
NP6 Zinc Sulfide (ZnS), NP7 ZnS:Mn 1.0% and NP8 
ZnO/ZnS. NPs were finally diluted and prepared for all 
experiments by vigorous sonication and addition of 
human serum albumin (HSA/ Sigma-Aldrich) at 1.5 
mg/ml to de-agglomerate them39.  
Synthesis of ZnO and Mn-doped ZnO NPs: These NPs 
were synthesized via wet-chemical techniques40,41. 
Briefly, 4 mmol of Zn acetate dihydrate were dissolved in 
40 ml of ethanol and heated at 50◦C with intense stirring 
for 30 minutes and this was the precursor “A”. Then 4 
mmol of sodium hydroxide were dissolved in 40 ml of 
ethanol and heated at 50◦C along with vigorous stirring 
for 1 hour, making in this way precursor “B”. 0.02 mmol 
of manganese acetate (dopant) were dissolved in 40 ml of 
ethanol at 50◦C along with vigorous stirring for 30 
minutes to produce precursor “C”. 20 ml of precursor 
“A” was then mixed with 20 ml of precursor “C”. Both 
solutions were heated at 80◦C for 30 minutes. After 
cooling 20 ml of precursor “B” were then added to the 
mixed solution with constant stirring. The new solution 
was kept in an oil bath at 65◦C for 2 hours. After cooling 
for 4 hours, the solution was centrifuged for 20 minutes at 
4000 rpm. The precipitate was washed and dried. The 
different Mn doping percentages applied on the surface of 
NPs were 0.5, 1.0, 1.5 and 2.0%. Un-doped ZnO NPs 
were synthesized with a similar procedure except for the 
addition of manganese acetate40,41 . (Zinc acetate 
dihydrate, sodium sulfide non-hydrate, manganese acetate 
tetrahydrate and sodium hydroxide were all purchased 
from Sigma-Aldrich). 
Synthesis of colloidal ZnS semiconductor nano-crystals 
capped with poly-vinylpyrrolidone (PVP) and prepared 
using 1% concentration of Mn+2 ion as a dopant: The 
NPs were synthesized via wet-chemical techniques42,43. 
Aqueous solution of 1.0 M Zn acetate dihydrate, 0.85 M 
sodium sulfide nonahydrate , and 0.010 M manganese (II) 
acetate tetrahydrate were prepared. 0.56 g of 
poly(vinylpyrrolidone) (PVP) was dissolved in 5 mL of 
the zinc acetate obtaining a concentration of 1.0 M. 5 mL 
of the manganese acetate solution was added to this 
solution. 5 mL of the sodium sulfide solution was then 
added slowly with stirring, thereby precipitating the 
nanoparticles. The solution was centrifuged for 10 
minutes at 3000 rpm and washed with deionized water. 
The nano-crystals were re-dispersed in water to make a 
0.01 M solution. Un-doped ZnS NPs were synthesized 
with a similar procedure except for the addition of 
manganese acetate42,43. (Zinc acetate dihydrate, sodium 
sulfide nonahydrate, manganese (II) acetate tetrahydrate, 
poly(vinylpyrrolidone) were all purchased from Sigma-
Aldrich). 
Preparation of ZnO/ZnS core shell NPs: The preparation 
of ZnO/ZnS core shell NPs was performed by thermal 
decomposition of Zn-3–Mercaptopropionic acid (MPA) 
complexes44,45. Briefly, 10 mL of a 0.1M zinc acetate 
dihydrate aqueous solution and 0.35 mL of MPA were 
mixed in a flask. This solution was diluted to 98 ml with 
water, the pH adjusted to 10.3 with 4M sodium hydroxide 
(NaOH) and satured with nitrogen (N2) by bubbling for 
20 min. ZnO NPs were dispersed in water to obtain a 
concentration of 0.01M and diluted to 43 mL with water 
and purged with  N2. 7 mL solution of Zn+2-MPA 
complex was added drop-wise to ZnO QDs and the 
mixture refluxed for 6 h. NPs were recovered by filtration 
and dried in an oven at 60◦C. (Zinc acetate dihydrate, 3- 
Mercaptopropionic acid and sodium hydroxide were all 
purchased from Sigma-Aldrich). 
Characterization of NPs: We decided to characterize in 
full detail only that type of NP with the best B-CLL 
cytotoxic effects when applying PDT and tested in vitro 
for viability and mortality of leukemic cells as later will 
be described. This further characterization was done by 
Transmission Electron Microscopy (TEM) (JEM-2100F, 
JEOL Inc.) and Scanning Electron Microcopy (SEM) 
(JEOL-JSM 6500 instrument and a Philips/ FEI, XL30s, 
FEG SEM / Phoenix EDAX) observation after de-
agglomeration of NPs with Human Serum Albumin 
(HSA) 1,5 mg/ml and intense sonication, as well as by 
elemental composition analysis by Energy dispersive X 
ray spectroscopy (EDS). Also, X-Ray Diffraction (XRD) 
measurements were carried out with a Diffractometer 
(D5000/Siemens) using Cu-Kα radiation with 
λ=0.154315 nm to determine the crystalline nature of the 
selected NPs. An UV-vis spectrophotometer (DU 800, 
Beckman Coulter) was used to study the optical 
absorption of NPs. Luminescence properties and SO 
generation by NPs was determined by photoluminescence 
(PL) spectroscopy, using a spectro-fluorometer 
(FluoroMax-2/Horiba Scientific) at room temperature 
with a 150mW continuous ozone-free Xe lamp. Fourier-
transformed infrared (FTIR) spectra was recorded using 
an attenuated total reflection Fourier Transform Infrared 
(FTIR-Varian 3100 FT-IR/Bio-Rad) to evaluate and 
characterized the presence of functional groups on the 
surface of these NPs. 
Penetration of cells by NPs:0.1, 0.2 and 0.3 mg/mL of 
each of the eight NPs produced were incubated with 
4x106 cells in 2 ml of culture medium for a maximum 
period of three hours, under conditions already described. 
NPs penetration of cells was determined by TEM and by 
fluorescence microscopy (Motic Inverted Microscope 
AE30-31 with Episcopic-Fluorescence Attachment EF-
INV-II) using a DAPI filter. Degree of penetration was 
determined by 3 independent pathologists observers 
trained in cell observation with TEM by evaluation of 5 
pictures taken at every each time point (0, 30, 60, 120 and 
180 minutes) of incubation of the cells with the different 
NPs and its selected concentrations mentioned before. 
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For this purpose, cells with NPs were summited to two 
washing cycles and finally to a re-supension step in PBS 
before TEM observation was performed. Results were the 
mean of the penetration scores given by all the observers 
to the 5 pictures for each specific NP and its different 
concentrations at every time point. Finally the level of 
penetration was ranked in relation of the total cell surface 
covered with NPs as none (0-5%), discrete (6-45%), 
moderate (46-75%) or intense (76-100%) as seen in each 
TEM picture by each observer. The time at which the 
highest level of cell penetration by NPs occurred, was 
later used as the best time point for all laser irradiation 
experiments. When maximum NPs cell penetration was 
determined by TEM, confirmation of this data was done 
by observation of cells under fluorescence microscopy 
using a DAPI filter in which the cells were supposed to 
fluorescence when penetrated by NPs. 
Photodynamic Therapy (PDT) Procedures: PDT was 
implemented by the use of a green laser (EVO Series-3B-
Wicked Laser) with a wavelength of 532 nm and 75 mw 
of power in order to irradiate the samples. The sample 
containing 4 million cells in 2ml of PBS was incubated 
with NPs and DPBF (1,3-diphenylisobenzofuran-
DPBF/Aldrich) as the chemical quencher46-48. The 
concentration of DPBF used in these probes was 6.0x10-5 
M and for NPs it was that one that produced the most 
intense penetration of cells in previous experiments at the 
shortest time point. After the selected time for cell 
incubation with NPs and the quencher, the samples with a 
total volume of 2 ml were mixed in a quartz cuvette and 
immediately irradiated with the laser light source. The 
light laser was kept constant at 40 cm from the samples in 
order to irradiate them inside a dark black box specially 
constructed for these purposes. This method used a 
standard photosensitizer of a known SO quantum yield. 
In our case we used Rose Bengal (RB) at 1.0x10-5 M 
with a high quatum yield (QY) of SO (ΦΔ=0.75)35,49,50. 
Then, SO quantum yields were determined by monitoring 
the disappearance of the quencher´s bands from their 
respective photoluminescence spectra, using an excitation 
source of 410 nm under continuous irradiation. 
Fluorescence was measured with a spectro-fluorometer 
(FluoroMax2) with a 150mW continuous ozone-free Xe 
lamp as the excitation source. Fluorescence data was 
collected every 2 seconds and up to a total time of 14 
seconds of laser irradiation with a rest period between 
irradiations of 2 minutes to later correlate with all the 
viability tests done on both cells the B-CLL and the 
healthy ones. Cells were cultured and incubated either 
with NPs in 96 micro-wells plastic plates or in 2.5 ml 
cryo-vials for 24 and/or 48 hours after irradiation as 
needed. Similarly we analyzed the variations of another 
fluorescent probe, Singlet Oxygen Sensor Green (SOSG-
Molecular Probes/Invitrogen) for the measurement of 
SO32,51. In this way again, 4 million leukemic or normal 
cells/2 ml of PBS, were incubated with the selected 
concentration of NPs and 5 ul/ml of SOSG, during the 
selected incubation time and later on using an 
excitation/emission of 485-495 nm for its detection while 
all fluorescence data was recorded every minute and up to 
a total time of 7 minutes of laser irradiation, with a rest 
period between irradiations of 2 minutes. 
Measurement of Intracellular Singlet Oxygen (SO) 
Production: For the measurement of intracellular SO 
production and its variations a novel and innovative 
method was thought and implemented by us. Briefly, 
determination of the intracellular SO generation quantum 
yield after incubation of both types of cells with NPs was 
done by fluorometry quantitative analysis of 
photooxidation reactions either using DPBF at 6.0x 10-
5M as the quencher or SOSG at 5.0 μL/mL as a 
fluorescent probe for SO, after the administration of PDT. 
Incubation of cells with SOSG was done for 2 and 3 
hours followed by observation of its penetration inside 
cells by fluorescence microscopy and lightening of the 
cells for 10 minutes with the microscope´s fluorescence 
lamp, using a double simultaneous Nikon filter for both 
FITC and DAPY. SOSG should make penetrated cells 
fluorescent under the lamp stimulation in the green color 
range similar to that of FITC. By doing this, we selected 
the best time period for incubation of cells with SOSG 
which was found to be 2 hours. Then, centrifugation of 
the cells was done in complete darkness for 40 minutes, 
followed by determination of the presence of any residual 
SOSG in the supernatants by fluoroscopic measurement. 
After this, re-suspension of the cells in 
new PBS was done with centrifugation for another 30 
minutes 2 more times, exchanging every time the 
supernatant by new PBS. Measurement of no residual 
SOSG was supposed to be reached in the final 
supernatant, or more cycles of washing and centrifugation 
were performed until no trace of SOSG could finally be 
found in it. At the end, re-suspension of cells in new PBS 
and measurement of intracelular emission at SOSG 
wavelength by fluoroscopy analysis was performed after 
PDT as mentioned before. The same procedure was then 
reproduced but using DPBF instead of SOSG, at a non 
toxic concentration for either kind of cell, observing and 
registering the changes in its levels, specially the decrease 
of its fluorescence emission intensity, in a time dependent 
manner. 
Determination of Cell Viability and Mortality: To 
determine NPs and PDT effects on cell viability we used 
a vital dye staining technique with acridine 
orange/propidium iodine (Fluoroquench/One-Lambda) as 
well as MTT (4,5dimethylthiazol-2-
5diphenyltetrazolium) assays. In this way 2x105 cells 
were incubated in 200 ul of medium with FBS inside 
each of the 96 micro-wells of the mentioned plastic 
disposable sterile culture trays. Three concentrations, 0.1, 
0.2 and 0.3 mg of each of the 8 NPs per ml of medium, 
were used in all the cytotoxicity tests performed in B 
normal lymphocytes and B-CLL cells, using the 
described vital staining technique with Fluoroquench and 
fluorescence microscopy observation in which, dead cells 
were seen red and living ones green. Also MTT probes 
were used for these same purposes. Results were the 
mean of the mortality rates observed in the 5 healthy 
donors (H) and the 5 leukemic patients (L) cells tested 
and exposed to each of the 3 selected concentrations of 
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each NP used. After the viability testing by Fluoroquench 
observation and MTT tests of all the 8 NPs on both types 
of cells, the one that could cause the greater mortality in 
B-CLL cells after PDT was chosen to continue all other 
experiments and characterizations. As soon as the most 
powerful cytotoxic NP was selected, its IC50 (the amount 
of that NP needed in vitro to kill 50% of the tested cells 
in a 24 hour incubation time) was determined by MTT 
and Flow Cytometry analysis. AnnexinV–fluorescein 
isothiocyanate (annexin V–FITC) and Propidium Iodine 
were used for Flow Cytometry (BD Becton-Dickinson 
FACS Verse) measurements of cell apoptosis and 
viability respectively. Cells were always centrifuged and 
re-suspended in PBS immediately before their use in the 
fluorometric measurements. Fluorometric analysis of the 
cell products with NPs were performed with a spectro-
fluorometer as mentioned before and always using a 
concentration of 2 x106 cells/ml of PBS in quarts cuvetts 
to a full volume of 2 ml irradiated in a black dark box 
using the same green laser and irradiation times and 
distance already described in this paper. For fluoroscopy 
analysis a new method was thought and implemented by 
us as said before. In all experiments, control samples at 
each time point were collected and the NPs induced cell 
death was determined at 24 and 48 hs of culture. Also, 
measurement of free ion Zn after incubation of the 
selected NPs in ultrapure water for 72 hs was performed 
by a conventional method. In this way, it was planned to 
test in further cytotoxicity tests, the Zn concentration that 
could potentially be found as a consequence of NPs 
dissolution and see if Zn by itself and in those 
concentrations could be responsable for some of the 
killing activities on normal and/or B-CLL cells. 
Statistical Analysis: Data were expressed as mean plus or 
minus the confidence interval 95 % (CI). T test was used 
to compare the mean values of the different experimental 
groups and control samples treated with NPs with and 
without PDT. The one-way analysis of variance 
(ANOVA ) was used to compare the values of the control 
samples with sample time points of B-CLL cells at 24 
and 48 hours of incubation with NPs. The flow cytometry 
histograms were obtained and analyzed with the software 
CellQuestPro. The correlation between the levels of SO 
and NPs2 cell sensitivity with and without laser 
irradiation was analyzed using Spearman correlation. P 




We first evaluated the effect of three different doses, 0.1, 
0.2 and 0.3 mg/ml of each of the 8 NPs produced by 
testing them for their penetration capacity into B-CLL 
cells as well as into normal B lymphocytes during a total 
culture period of 3 hours (Fig 1). NP1 as it has been said 
before corresponded to ZnO, NP2 to ZnO:Mn+2 0.5% 
doping, NP3 to ZnO:Mn+2 1.0% doping, NP4 to 
ZnO:Mn+2 1.5% doping, NP5 to ZnO:Mn+2 2.0% 
doping, NP6 to ZnS, NP7 to ZnS:Mn+2 1.0% doping and 
NP8 to ZnO/ZnS. The results of these experiments 
indicated that 0.2 mg/ml of each of the analyzed NPs, 
resulted in an intense cell penetration activity by all of 
them that was not further increased by its rising to a 
higher concentration of 0.3 mg/ml. Because of this, the 
concentration of 0.2 mg/ml of NPs was used in all further 
experiments. At time 0, no particles were seen inside any 
of the cells but at two hours time point all observers 
agreed there was a maximum “intense” similar 
penetration of all NPs in both type of cells . Normal 
lymphocytes as well as B-CLL cells were well and 
maximally penetrated by NPs at 0.2 mg/ml concentration 
when cultured at 37◦C during two hours and observed 
under TEM .  At three hours culture time no significant 
further increase in the amount of total NPs penetration 
into cells was observed either in leukemic or normal 
ones. B-CLL cells as well as normal B lymphocytes when 
incubated during this time period with 0.2 mg/ml of each 
of the NPs and observed under TEM and fluorescent 
microscopy were clearly and intensively penetrated by all 
of these NPs tested as described by the 3 observers and 
no increment of NPs penetration in cells was found after 
this time point as it was said. In this way an incubation 
period of 120 minutes with 0.2 mg/ml of NPs was 
selected as the best conditions for NPs penetration into 
cells. Then, we evaluated the effect of those same three 
different doses, 0.1, 0.2 and 0.3 mg/ml of each of the 8 
NPs on the viability of both B-CLL cells and normal 
lymphocytes at 24 and 48 hours of incubation after PDT 
(Fig 1). In these probes 0.2 mg/ml of each of the NPs 
tested, again resulted in the best B-CLL cell killing 
activity. Normal Lymphocytes also had the greatest 
mortality rates at this NPs concentration but were always 
significantly lower and mostly insignificant in relation to 
that observed for B-CLL cells (Fig 2). It was also seen 
that 0.1 mg/ml of each NP, had almost no significant 
difference in the viability of B-CLL cells in relation with 
that of the control samples without NPs except for NP2. 
Scaling up the NPs concentration to 0.3 mg/ml did not 
either significantly improved the cell killing activity of 
those same NPs in relation to that concentration of 0.2 
mg/ml. Then this concentration of 0.2 mg/ml was 
selected and used for all other experiments. From the 8 
NPs specially designed and produced for this study, 0.5% 
Mn-doped ZnO NPs, were chosen as the most powerful 
killing NPs against B-CLL cells when associated with 
PDT, but with minimum impact on normal lymphocytes. 
At the mentioned concentration of 0.2 mg/ml, NPs2 
(0.5% Mn doped ZnO NPs) were the most effective NPs 
in relation to its killing activity of B-CLL cells (Fig 1). In 
this way NP2 was selected for the performance of all 
other characterization and cytotoxicity procedures. This 
type of NP had an absorbance spectrum with a well 
defined band at 364 nm. They showed a predominant 
energy band-gap of 3.5 Ev.. The emission spectrum of 
these NPs had one weak band in the UV region around 
397 nm that could be attributed to their band-gap as well 
as another broad one at 542 nm in the visible region 
which could be related to oxygen defects. Processes in 
which transitions with the photo-generated holes at the 
surface of the NPs are trapped by O2-ions are probably 
responsible for the visible emission of those NPs. Doping 
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with Mn could increase these surface defects of NPs and 
improve the action of PDT.. X-Ray Diffraction (XRD) 
patterns of ZnO:Mn+2 NPs showed several peaks with 
2Ɵ of 31.67°, 34.31°, 36.14°, 47.40°, 56.52°, 62.73°, 
66.28°, 67.91° and 69.03° corresponding to (100), (002), 
(101), (102), (110), (103), (200), (112) and (201) planes), 
indicating an hexagonal wurtzite structure23,52. No 
additional peaks related to any other impurities were 
detected. The average crystallite size of these Mn doped 
ZnO NPs was calculated from the XRD patterns using 
Scherrer’s formula [55], being 14.41 ± 4.95nm. Fourier 
Transform Infrared (FTIR) spectrum of these 0.5% Mn 
doped ZnO NPs confirm the formation of Zn-O and Mn-
O bonds in the crystal structure [52].  By scanning 
electron microscopy (SEM) and transmission electron 
microscopy (TEM) after being well de-agglomerated 
using HSA and intense sonication39, most of the NPs had 
spherical shapes with an average size of 20-25 nm. The 
resulting 0.5% Mn doped ZnO NPs morphology was 
quite similar in both analysis (TEM and SEM) being 
observed as an homogeneous population of NPs of that 
mentioned size. TEM and SEM images showed that the 
NPs, appeared a little larger in size than the same 
estimated result from Scherrer analysis. Energy 
dispersive X ray spectroscopy (EDS)53,54 analysis of 
ZnO:Mn+2 NPs confirmed the elemental composition of 
these NPs. The presence of Zn and oxygen was 
demonstrated as was observed in the obtained 
corresponding EDS peaks. The presence of Au, Si, Cl, Ca 
and K was probably due to interferences mixed while 
sample preparation. As observed by TEM both types of 
cells could undergo a process of cell death after 0.5% Mn 
doped ZnO NPs treatment with or without PDT, 
corresponding to features of autophagy, but this 
phenomenon was always stronger when PDT was applied  
.This autophagic cell death was specially pronounced, 
much more advanced, massive and faster on B-CLL cells, 
affecting almost all of them treated in this way  (Fig 3). In 
the other hand, normal B lymphocytes, only suffered 
autophagyc changes in a very lesser degree and basically 
in the form of an isolated pattern in which only few cells 
went through this dying pathway beside being treated in 
the same way and during the same period of time. In this 
scenario of autophagy, the formation of doublemembrane 
bound organelles predominated in B-CLL cells when 
treated with 0.5% Mn doped ZnO NPs alone but 
predominantly when PDT was simultaneously applied. 
These organelles were clearly autophagosomes and by 
this specific detail the observed dying process can 
undoubtedly be considered as autophagy (Fig 3), which 
denotes any cellular pathway involving the delivery of 
cytoplasmic material to the lysosome for degradation55-57. 
Changes in the production of intracellular SO was 
detected in both normal and B-CLL cells after being 
penetrated by NPs and laser irradiated. But the increase of 
intracellular SO was significantly higher in B-CLL cells 
than in normal B lymphocytes (p<0.04). Measurements of 
the intracellular SO generation quantum yield after PDT 
was done by fluorometry quantitative analysis of photo-
oxidation reactions either using DPBF as the quencher or 
SOSG as a fluorescent probe for singlet oxygen, as 
previously described. B-CLL cells as well as normal B 
lymphocytes when incubated during two hours with 
SOSG and observed under fluorescent microscopy were 
clearly penetrated by this fluorescent probe (Fig 4). The 
measurement of the intracellular fluorescence spectra of 
SOSG in the presence of 0.5% Mn doped ZnO NPs inside 
B-CLL cells and normal B lymphocytes was possible 
using our described method and recording its changes 
every minute up to 7 minutes upon irradiation . A 
selective increase in the intensity of fluorescence of 
SOSG specially in B-CLL cells as a result of the larger 
production of intracellular SO induced by the action of 
light when these 0.5% Mn doped ZnO NPs have already 
penetrated these cells was recoreded. SO quantum yields 
were determined with the graph of time dependent of 
SOSG in the presence of NPs inside cells after PDT . 
Quantitative comparison of the intracellular SO 
generation between normal lymphocytes and B-CLL 
cells, both treated with Mn 0.5% doped ZnO NPs and 
PDT, using this SOSG fluorescent probe, showed a 
significant increased in SO generation in malignat 
leukemic cells rather than in normal ones (p<0.04) (fig 5 
a and b). The quantum yield was calculated using 
equation 158  and it was 0.88 in B-CLL cells and 0.49 in 
normal lymphocytes using SOSG as a fluorescent probe 
for SO, being this difference significant (p<0.04) (Fig 5 
a). In the equation 1 ΦΔsample= ΦΔref where ΦΔref is 
SO quantum yield of Rose Bengal (RB), and Ksample as 
well as Kreference are the slopes of the plot of the time-
dependent increase of SOSG, expressed as the increase of 
fluorescence at 526 nm of the measured of the Mn 0.5% 
doped ZnO NPs and the RB, respectively . The other 
method used to calculate the production of intracellular 
SO was that in which DPBF performed as the chemical 
quencher in a decomposition reaction. In the analysis of 
DPBF oxidation by SO, Ksample andKreference are the 
slopes of the plot of the time-dependent decomposition of 
DPBF,expressed as the decrease of fluorescence at 453 
nm of the measured Mn 0.5% doped ZnO NPs and the 
RB, respectively . In this way SO production was 
significantly higher in B-CLL cells compared to normal 
lymphocytes when both types of cells were treated with 
NPs and PDT (p<0.03)46,58,59 (Fig 6 a and b). 
Fluorescence spectra photo-oxidation of DPBF in the 
presence of Mn 0.5% doped ZnO NPs inside B-CLL cells 
showed that DPBF reacts with SO, causing a progressive 
decrease in the intensity of the quencher. This 
decomposition of DPBF by SO produced by the use of 
RB and Mn 0.5% doped ZnONPs in B-CLL cells was a 
time dependent phenomenon and again there was an 
increased production of intracellular SO much higher in 
B-CLL cells than in normal lymphocytes when PDT was 
delivered (p<0.03) (fig 6 a and b). The quantum yield of 
SO for B-CLL cells was 0.21 and 0.10 for normal 
lymphocytes using DPBF as the chemical quencher. Then 
it is clear that a similar phenomenon was observed in 
both cases when SOSG or DPBF were used respectively. 
SO production was found to be increased both in normal 
and B-CLL cells when cultured with 0.5% doped ZnO 
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NPs and laser irradiated, but this increased in SO 
production was always significantly higher in B-CLL 
cells compared to normal lymphocytes . This intracellular 
increased of SO production correlated well with cell 
mortality as it will be described later. After 24 hours in 
culture, both healthy (H) and leukemia (L) cells without 
NPs, had a spontaneous cell death of 5 and 20% 
respectively (fig 2). Cell irradiation with lasers showed 
no  statistical difference in terms of apoptosis or mortality 
in both cell populations at this time, when no NPs were 
used . However, when cultured during the same period of 
time, but exposed to Zn NPs, B-CLL cells without 
irradiation, showed an important lost of viability specially 
if culturing time is prolonged to 48 hours. Percentages of 
cytotoxicity increased significantly with PDT at 24 and 
48 hours in B-CLL cells cultured with NPs . Cytotoxicity 
levels produced by each of the NPs described before on 
B-CLL cells compared to that on normal B lymphocytes 
at 24 and 48 hours with and without laser irradiation, was 
in all cases significantly higher  (Fig 2). At the 0.2 mg/ml 
concentration, NP2 (Mn doped 0.5% ZnO NPs) was the 
most effective NP in relation to killing activity of B-CLL 
cells while having a minimum effect on normal B 
lymphocytes . Mn doped 0.5% ZnO NPs effectively 
eliminated the largest amount of fludarabine-resistant B-
CLL cells with almost no lost produced in the viability of 
normal healthy lymphocytes. Maximum increased in 
mortality of B-CLL cells was achieved with NPs2 at 48 
hours when PDT was applied. Apoptosis levels for 
irradiated and non-irradiated cells cultured with NPs 2 at 
24 and 48 hs detected by flow cytometric analysis 
(annexin V/PI double staining) was always significantly 
higher in B-CLL cells compared to normal lymphocytes 
(p<0.01) (Fig 7). Apoptotic normal B lymphocytes and 
B-CLL cells at 24 hours cultured with NPs2 were 14 and 
49%, while these percentages moved up after laser 
irradiation (PDT) to 28 and 90% ( p<0.01) respectively 
(Fig 7). Comparison of the mean IC50 of Mn 0.5% doped 
ZnO on B-CLL cells (n = 5) and normal lymphocytes (n 
= 5) clearly showed a significant difference when NPs2 
were used to treat B-CLL cells (p<0.04). Fludarabine 
resistant B-CLL cells were clearly much more sensitive 
to NPs2, with an IC50 value of 0.1 mg/ml while normal 
lymphocytes had a value a lot above and significantly 
higher for that same NP2 (p<0.04) (Fig 8). MTT assays 
comparing the action of NPs on the mortality of primary 
B-CLL cells isolated from the blood samples of the 5 
CLL patients (L), that were considered clinically 
Fludarabine resistant with un-mutated Ig VH to that of 
normal B lymphocytes from healthy subjects (H), clearly 
showed that the dose dying response to NPs2 in the 
Fludarabine resistant B-CLL cells was significantly 
greater than that observed in normal lymphocytes 
(p<0.01) (Fig 7). SO production was both found to 
increase in normal and B-CLL cells when cultured with 
NPs2, this increase in SO production was significantly 
higher in B-CLL cells compare to normal lymphocytes 
(p<0.03). No dosable free ion Zn was found in the 
ultrapure water with NPs2 after 72 hours of incubation. 
Tests of cytotoxicity with the possible amount of free ion 
Zn that could have been determined in these 
measurements were not further necessary as no free Zn 
was detected at all in the analyzed ultrapure water. 
 
CONCLUSION 
Metal NPs, could be an optional effective and specific 
treatment for drug resistant forms of B-CLL13,60. We 
produced and tested a variety of metal Zn NPs of which 
one made of 0.5% Manganese Doped Zinc Oxide (0.5% 
Mn-doped ZnO) was finally selected for further 
characterization and testing as it had the best killing 
activity in vitro for fludarabine resistant and un-mutated 
Ig VH B-CLL cells, specially when combined with PDT. 
Mn-doped ZnO NPs have distinct effects on cell viability 
via killing of B-CLL cells with low toxicity to normal 
lymphocytes. These NPs induced a predominant process 
of autophagy leading to massive death of B-CLL cells 
related to a higher production of SO61,62. This type of NPs 
could increase selectively and rapidly, just by themselves, 
the intracellular levels of SO in B-CLL cells conducting 
them to an autophagyc death program that could 
irreversibly kill them easily but very strongly when 
delivered with PDT. Using this kind of treatment, B 
lymphocytes, persist mostly alive and not harmed at all, 
either by these NPs, PDT, or its combination, as it has 
been said here. We have seen that very small variations of 
intracellular SO concentrations in leukemic cells, could 
execute and accelerate these deadly programs in these 
therapy resistant cells13,14, being this mechanism 
potentiated and increased by the concomitant delivery of 
PDT, rendering normal cells almost untouched. Our 
intracellular SO measurement method proved to be good 
enough, inexpensive and quite simple to perform that it 
could easily be introduced soon as a routine diagnostic 
tool. We investigated the mechanisms of cell death during 
PDT using fluorescence microscopy and imaging and 
performing fluorometric measurements to help in the 
design of better treatments for resistant forms of B-CLL. 
We can envision external devices for blood irradiation by 
PDT after NPs treatment, or even though “intelligent” 
ZnO NPs with self assemblies for energy discharge and 
light emission from the same NPs or even “hybrids” of 
biodegradable nanoparticles coated with specific 
monoclonal antibodies and loaded with ZnO NPS . As 
this therapy seems to be very specific to fludarabine 
resistant B-CLL cells, with almost no damage made to 
normal lymphocytes, it could contribute in the near future 
as a new innovative targeted strategy to be delivered in 
the clinical setting, for the definitive benefit not only of 
these bad prognostic patients but also for all the other 
indolent lymphomas as well as other types of cancer. 
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